Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes

Comparison of the Effect of Insulin Detemir Versus Insulin NPH Both With Insulin Aspart on Weight Change in Overweight and Obese Subjects With Type 2 Diabetes

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00504673

Acronym

PREDICTIVE™

Enrollment

277

Registered

2007-07-20

Start date

2005-04-30

Completion date

2006-12-31

Last updated

2023-11-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes, Diabetes Mellitus, Type 2

Brief summary

This trial is conducted in Europe. The purpose of the trial is to investigate the effect of insulin detemir on weight change in overweight and obese patients with type 2 diabetes.

Interventions

DRUGinsulin detemir

DRUGinsulin NPH

DRUGinsulin aspart

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* HbA1c: 7.5-11.0% * BMI: 25-40 kg/m2

Exclusion criteria

* Treatment with any OAD (Oral Antidiabetic Drugs) except metformin

Design outcomes

Primary

Measure	Time frame
Body weight loss	after 26 weeks of treatment

Secondary

Measure	Time frame
HbA1c	—
Incidence of hypoglycaemia	—

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 9, 2026